術後以外の急性疼痛市場 - 市場の洞察、疫学、市場予測：2032年

米国における術後以外の急性疼痛の発生件数は2019年に約51,000,000件でした。米国では、術後以外の急性疼痛と診断された患者の約50％が中等度の重症度を経験していました。また、術後以外の急性疼痛の総治療件数は約42,000,000件でした。

近年、急性疼痛管理市場には大きな変化が見られます。オピオイドはゴールドスタンダードでありましたが、Multimodal analgesia（MMA）モデルに取って代わられつつあります。非ステロイド性抗炎症薬は、シクロオキシゲナーゼ1および2（COX-1およびCOX-2）を阻害することにより、抗炎症作用、解熱作用、鎮痛作用、血栓抑制作用を発揮します。NSAIDsにはいくつかのジェネリック医薬品があるが、ジェネリック医薬品が市場に出回っているのは特許が切れたためです。

さらに、NSAIDsはオピオイドの消費量を50％以下に減少させ、オピオイドと併用した場合に優れた鎮痛効果を発揮することが認められており、軽度から中等度の疼痛に対する第一選択薬として提案されているが、いくつかの副作用を有しています。

米国における術後以外の急性疼痛の市場規模は、2022年に30億米ドル近くとなりました。同市場は2032年まで拡大すると予測されています。

当レポートでは、米国における術後以外の急性疼痛市場について調査し、市場の概要とともに、疫学、患者動向、新たな治療法、2032年までの市場規模予測、および医療のアンメットニーズなどを提供しています。

目次

第1章 重要な洞察

第2章 レポートのイントロダクション

第3章 術後以外の急性疼痛のエグゼクティブサマリー

第4章 術後以外の急性疼痛の市場概要

第5章 主要な出来事

第6章 疫学と市場調査手法

第7章 疾患の背景と概要

• イントロダクション
• 急性疼痛と慢性疼痛
• 急性疼痛の種類
• 兆候と症状
• 術後以外の急性痛の原因
• 診断

第8章 治療

• 薬理学的管理
• 急性疼痛に対する非薬物療法
• 治療ガイドライン

第9章 疫学と患者数

• 主な調査結果
• 前提条件と理論的根拠：術後以外の急性痛
• 米国における疫学シナリオ

第10章 患者動向

第11章 上市済み薬剤

第12章 新興薬剤

第13章 術後以外の急性疼痛：米国市場分析

• 主な調査結果
• 市場の見通し
• コンジョイント分析
• 主要な市場予測の前提条件
• 米国の市場規模

第14章 アンメットニーズ

第15章 SWOT分析

第16章 KOLの見解

第17章 市場アクセスと償還

• 米国
• 術後以外の急性疼痛の市場アクセスと償還

第18章 付録

第19章 DelveInsightのサービス内容

第20章 免責事項

第21章 DelveInsightについて

List of Tables

• Table 1: Summary of Non-postoperative Acute Pain Market and Epidemiology (2019-2032)
• Table 2: Acute vs. Chronic Pain in the ED
• Table 3: Most Common Types of Pain (related to acute Non-postoperative pain)
• Table 4: Graded Chronic Pain Scale (GCPS)
• Table 5: Total Incident Cases of Non-postoperative Acute Pain in the United States (in thousands) (2019-2032)
• Table 6: Type-specific Cases of Non-postoperative Acute Pain in the United States (in thousands) (2019-2032)
• Table 7: Severity-specific Cases of Non-postoperative Acute Pain in the United States (in thousands) (2019-2032)
• Table 8: Total Treated Cases of Non-postoperative Acute Pain in the United States (in thousands) (2019-2032)
• Table 9: Comparison of Marketed Drugs
• Table 10: LICART (diclofenac epolamine), Clinical Trial Description, 2023
• Table 11: UBRELVY (ubrogepant), Clinical Trial Description, 2023
• Table 12: REYVOW (lasmiditan), Clinical Trial Description, 2023
• Table 13: ZAVZPRET (zavegepant), Clinical Trial Description, 2023
• Table 14: NURTEC ODT (rimegepant), Clinical Trial Description, 2023
• Table 15: Comparison of Emerging Drugs
• Table 16: VX-548, Clinical Trial Description, 2023
• Table 17: Eptinezumab, Clinical Trial Description, 2023
• Table 18: STS101 (DHE Nasal Powder), Clinical Trial Description, 2023
• Table 19: AXS-07, Clinical Trial Description, 2023
• Table 20: Naltrexone-Acetaminophen, Clinical Trial Description, 2023
• Table 21: Key Market Forecast Assumption of Non-postoperative Acute Pain in the United States
• Table 22: Total Market Size of Non-postoperative Acute Pain in the US, USD million (2019-2032)
• Table 23: Market size of Non-postoperative Acute Pain by Therapies in the US, USD million (2019-2032)

List of Figures

• Figure 1: Epidemiology and Market Methodology
• Figure 2: Types of Pain Based on Duration
• Figure 3: Wong-Baker Faces Pain Rating Scale
• Figure 4: Signs and Symptoms of Acute Pain
• Figure 5: Efferent Nociceptive Pathway
• Figure 6: Present Pain Intensity (PPI)
• Figure 7: Present Pain Intensity (PPI) for Diagnosis
• Figure 8: Total Incident Cases of Non-postoperative Acute Pain in the United States (2019-2032)
• Figure 9: Type-specific Cases of Non-postoperative Acute Pain in the United States (2019-2032)
• Figure 10: Severity-specific Cases of Non-postoperative Acute Pain in the United States (2019-2032)
• Figure 11: Total Treated Cases of Non-postoperative Acute Pain in the United States (2019-2032)
• Figure 12: Total Market Size of Non-postoperative Acute Pain in the US, USD million (2019-2032)
• Figure 13: Market size of Non-postoperative Acute Pain by Therapies in the US, USD million (2019-2032)
• Figure 14: Health Technology Assessment

Key Highlights:

• Incident cases of non-postoperative acute pain in the United States were approximately 51,000,000 in 2019.
• In the United States, about 50% of the individuals diagnosed with non-postoperative acute pain experienced a moderate level of severity.
• In the United States, total treated cases for non-postoperative acute pain were nearly 42,000,000
• In recent years, extensive changes have been observed in the acute pain management market. Opioid replacement with other more beneficiary approaches has been in talks; opioid was a gold standard but is being replaced by multimodal analgesia (MMA) models.
• NSAIDs provide anti-inflammatory, antipyretic, analgesic, and thrombotic effects by inhibiting cyclooxygenases 1 and 2 (COX-1 and COX-2). Although several generics are available for NSAIDs, and presence of generics in the market is due to patent expiration.
• Moreover, NSAIDs have been recognized to decrease opioid consumption by less than 50%, provide superior analgesia when combined with opioids, have been proposed as first-line medications for mild-to-moderate pain, and possess several side effects.
• EMGALITY provides patients with the first FDA-approved drug that reduces the frequency of attacks of episodic cluster headache, an extremely painful and often debilitating condition.
• Calcitonin gene-related peptide (CGRP) plays a vital role in the pathophysiology of migraine and cluster headaches. Eptinezumab, developed by Lundbeck, is a monoclonal immunoglobulin G1 antibody that strongly and specifically binds to human CGRP, targeting both the a- and B-forms of CGRP. Approved by the US FDA in 2020 under the name VYEPTI, the drug is designated for the preventive treatment of migraines.
• Some of the most prominent new therapies in the pipeline include VX-548, Dihydroergotamine, AXS-07, Eptinezumab, and Naltrexone-acetaminophen.

DelveInsight's " Non-postoperative Acute Pain - Market Insights, Epidemiology, and Market Forecast - 2032" report delivers an in-depth understanding of the Non-postoperative acute pain, historical and forecasted epidemiology as well as the non-postoperative acute pain market trends in the United States.

The non-postoperative acute pain market report provides current treatment practices, emerging drugs, Non-postoperative acute pain market share of the individual therapies, and current and forecasted Non-postoperative acute pain market size from 2019 to 2032, segmented by seven major markets. The report also covers current Non-postoperative acute pain treatment practices/algorithms and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.

Geography Covered:

• The United States

Study Period: 2019-2032.

Non-postoperative Acute Pain Disease Understanding and Treatment Algorithm

Non-postoperative Acute Pain Overview

Non-postoperative pain refers to acute pain that arises from various causes unrelated to surgical procedures. It can result from conditions such as any injury, illness, trauma, burns, cuts, infection, or tissue damage. The pain may manifest in different regions of the body, requiring a systematic diagnostic approach involving patient history, physical examination, and, if necessary, imaging or laboratory tests. The goal is to identify the source and nature of the pain to tailor an appropriate treatment plan. Non-postoperative acute pain management may involve analgesic medications, physical therapy, and addressing the underlying condition. A multidisciplinary approach is often necessary to ensure comprehensive care and effective pain relief for individuals experiencing non-postoperative acute pain.

Non-postoperative Acute Pain Diagnosis

Diagnosing non-postoperative acute pain involves a comprehensive approach. A detailed medical history is obtained, including the onset, duration, and characteristics of the pain, along with relevant patient information. A thorough physical examination is conducted to identify visible signs of injury or inflammation, assess tenderness and swelling, and evaluate range of motion. Diagnostic tests, such as X-rays or MRI scans, may be employed to visualize internal structures. Specialized consultations with relevant specialists may be sought, and nerve blocks or injections could be used for diagnostic purposes. Lifestyle factors, psychosocial elements, and any exacerbating or alleviating factors are considered. The goal is to systematically gather information to pinpoint the source of pain and formulate an effective treatment plan.

Further details related to diagnosis will be provided in the report…

Non-postoperative Acute Pain Treatment

Acute pain is caused by injury, surgery, illness, trauma, or painful medical procedures. It serves as a warning of disease or a threat to the body. It generally lasts briefly and disappears when the underlying cause has been treated or healed. Multimodal treatment is crucial for optimizing pain relief. Because different modalities may be additive or synergistic, this approach can also reduce the potential for side effects. The cornerstones of multimodal treatment include nerve blocks or epidurals, opioids or other analgesics, adjunctive medications, physical modalities (RICE), and rehabilitation; psychosocial interventions, including distraction, meditation, and deep breathing, are also central components. The treatment pattern currently consists of different approaches classified into pharmacologic and nonpharmacological therapies.The current market offers treatment with opioids, NSAIDs, and other anesthetics. The effectiveness of pain relief is of the utmost importance to anyone treating patients undergoing surgery. Consequently, the pain market is looking forward to new therapies that contribute substantially to ease the pain.

Further details related to treatment will be provided in the report…..

Non-postoperative Acute Pain Epidemiology

The Non-postoperative acute pain epidemiology chapter in the report provides historical as well as forecasted epidemiology segmented by Total Diagnosed Incident Cases of Non-postoperative acute Pain, Type-specific Cases of Non-postoperative acute Pain, Severity-specific Cases of Non-postoperative acute Pain, and Total Treated Cases of Non-postoperative acute Pain in the United States.

• The total incident cases of Non-postoperative acute pain in the United States were ~53,000,000 cases in 2022.
• In 2022, total type-specific incident cases of Non-postoperative acute pain in the United States comprised ~54,000,000 and ~38,000,000 cases for trauma pain and others, respectively, which are anticipated to increase during the forecast period.
• In the United Sttaes, severity-specific incident cases of Non-postoperative acute pain were highest in moderate pain, accounting for ~ 25,000,000 cases in 2022.
• The total treated cases of Non-postoperative acute pain in the United States was found to be ~43,000,000 cases in 2022, which might increase during forecast period.

Non-postoperative Acute Pain Drug Chapters

The drug chapter segment of the Non-postoperative acute pain report encloses a detailed analysis of the marketed and late-stage (Phase III) pipeline drug. The marketed drugs segment encloses drugs such as ELYXYB (Scilex Holding), ZAVZPRET (Pfizer), NURTEC ODT (Pfizer/Biohaven Pharmaceutical), and others. Furthermore, the current key players for emerging drugs and their respective drug candidates include STS101 (Satsuma Pharmaceuticals), AXS-07 (Axsome Therapeutics), and others. The drug chapter also helps understand the Non-postoperative acute pain clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, and the latest news and press releases.

Marketed Drugs

ELYXYB (celecoxib): Scilex Holding

ELYXYB is a nonsteroidal anti-inflammatory drug (NSAID) and the first and only ready-to-use oral solution designed to deliver fast and long-lasting migraine relief with the proven safety of COX-2 selectivity that is FDA-approved for acute treatment of migraine, with or without aura, in adults. ELYXYB oral solution is made using a self-micro emulsifying drug delivery system that enables celecoxib to be absorbed better and work faster. The product works within 1 h to provide relief from a migraine attack. It is thought to work by inhibiting an enzyme called cyclooxygenase-2 (COX-2), which inhibits the production of a group of lipids called prostaglandins. Prostaglandins can cause inflammation and pain. In February 2023, Scilex Holding announced the commercial launch of ELYXYB in the US.

ZAVZPRET (zavegepant): Pfizer

ZAVZPRET is a third-generation, high affinity, selective, and structurally unique, small molecule CGRP receptor antagonist and the only CGRP receptor antagonist in clinical development with both intranasal and oral formulations. CGRP receptor antagonists work to treat migraine by reversibly blocking CGRP receptors, thereby inhibiting the biologic activity of the CGRP neuropeptide, which is thought to play a causal role in migraine. ZAVZPRET is a nasal spray administered as a single spray in one nostril, as needed. It may provide an important alternative for patients who need a quick onset of action or those who cannot take oral treatments due to nausea and vomiting at the time of migraine onset. In March 2023, the US FDA approved ZAVZPRET for the acute treatment of migraine with or without aura in adults.

Emerging Drugs

STS101 (DHE Nasal Powder): Satsuma Pharmaceuticals

STS101 is designed to provide significant benefits vs existing acute treatments for migraine, including the combination of quick and convenient self-administration and other clinical advantages that current DHE liquid nasal spray products and injectable dosage forms lack. The dry powder DHE formulation has demonstrated fast absorption, rapid achievement of high DHE plasma concentrations. STS101 combines the Satsuma powder technology with an easy-to-use nasal delivery device to create a reliable and convenient DHE product potentially able to provide the unique clinical advantages of DHE while overcoming the shortcomings of existing DHE products. The company has completed three Phase III trials, i.e. ASCEND (NCT04406649), SUMMIT (NCT04940390), and EMRGE (NCT03901482) supporting the safety and efficacy of STS101 in the acute treatment of migraine. In May 2023, Satsuma Pharmaceuticals announced that its 505(b)(2) New Drug Application (NDA) for STS101 for the acute treatment of migraine, has been accepted for review by the FDA.

AXS-07: Axsome Therapeutics

AXS-07 is a novel, oral, rapidly absorbed, multi-mechanistic, investigational medicine for the acute treatment of migraine. The drug consists of MoSEIC (Molecular Solubility Enhanced Inclusion Complex) meloxicam and rizatriptan. AXS-07 is thought to act by inhibiting calcitonin gene-related peptide (CGRP) release, reversing CGRP-mediated vasodilation, and inhibiting neuroinflammation, pain signal transmission, and central sensitization. Meloxicam is a new molecular entity for migraine enabled by MoSEIC technology, which results in rapid absorption of meloxicam while maintaining a long plasma half-life. AXS-07 is covered by more than 80 issued the US and international patents which provide protection out to 2036. Manufacturing activities related to the planned resubmission of the NDA for AXS-07 for the acute treatment of migraine continue to progress. The Company continues to anticipate resubmission of the NDA in the first half of 2024.

Drug Class Insight

The ongoing and future avenues include efforts to de-escalate therapy in Non-postoperative acute pain, improve the sequencing of available CGRP inhibitor, and introduce new biomarker-guided therapies into the armamentarium for Non-postoperative acute pain. There has also been considerable interest in improving the benefit conferred by Cyclo-oxygenase 2 (COX-2) inhibitor, particularly ELYXYB, after the agent's establishment as a standard of care in Non-postoperative acute pain.

Calcitonin gene-related peptide (CGRP) inhibitor

CGRP is involved in several of the pathophysiologic processes underpinning migraine attacks. Therapies that target CGRP or its receptor have shown efficacy as preventive or acute treatments for migraine. CGRP plays a role in gastrointestinal nociception, inflammation, gastric acid secretion, and motility. Small-molecule CGRP receptor antagonists (rimegepant and ubrogepant) are approved for the acute treatment of migraine. In March 2023, the US FDA also approved ZAVZPRE (zavegepant), the first and only calcitonin gene-related peptide (CGRP) receptor antagonist nasal spray for the acute treatment of migraine with or without aura in adults.

Cyclo-oxygenase 2 (COX-2) inhibitor

COX-2 inhibitors are a type of nonsteroidal anti-inflammatory drug (NSAIDs). NSAIDs relieve pain and fever and reduce inflammation. ELYXYB (celecoxib) is a NSAID and the first and only ready-to-use oral solution designed to deliver fast and long-lasting migraine relief with the proven safety of COX-2 selectivity that is FDA-approved for acute treatment of migraine, with or without aura, in adults. ELYXYB oral solution is made using a self-micro emulsifying drug delivery system that enables celecoxib to be absorbed better and work faster.

Non-postoperative Acute Pain Market Outlook

Treatment of acute pain is generally tailored to the individual patient's assessment and requirements. Acute pain usually lasts for less than 7 days but often extends up to 30 days for some conditions; acute pain episodes may recur periodically. In some patients, acute pain persists to become chronic. Pain is the most common reason for emergency department visits and is commonly encountered in primary care, other outpatient, and inpatient settings.

The treatment pattern currently consists of different approaches classified into pharmacologic and nonpharmacological therapies. The pharmacological therapies include analgesics that are further segregated into opioids, nonsteroidal anti-inflammatory drugs (NSAIDs), acetaminophen, corticosteroids, anesthetics, etc. Acute pain is also managed by the use of benzodiazepines, muscle relaxants, antidepressants, alpha-2 agonists, gamma-aminobutyric agonists, and cannabinoids. Further, nonpharmacological therapies include acupuncture, psychological approaches (cognitive behavioral therapy, mindfulness-based stress reduction), chiropractic manipulation, physical therapy, transcutaneous electrical stimulation, massage therapy, exercise, and other complementary and alternative medicine therapies (CAM). All these involve the concept known as multimodal analgesia.

In recent years, extensive changes have been observed in the acute pain management market. Opioid replacement with other more beneficiary approaches has been in talks; opioid was a gold standard but is being replaced by multimodal analgesia (MMA) models.

Among the approved drugs, UBRELVY is indicated for the acute treatment of migraine with or without aura in adults by the US FDA. REYVOW, which has a unique mechanism of action, is the first and only FDA-approved medicine in a new class of acute treatment for migraine. The US FDA has also approved EMGALITY solution for treating episodic cluster headaches in adults.

Many companies are working toward this therapeutic area, including Vertex, Charleston Laboratories, Allodynic Therapeutics, Satsuma Pharmaceuticals, Axsome Therapeutics, ALGOMEDIX, PULMATRIX, Relevium Medical, Neumentum Pharmaceuticals, Medical Developments International (MVP), H. Lundbeck, and others.

Key Findings

• The total market size in the United States for Non-postoperative acute pain was estimated to be nearly USD 3,000 million in 2022, which is expected to grow by 2032.
• The US market for Non-postoperative acute pain holds therapies like LICART, UBRELVY, REYVOW, NURTEC ODT, and others.
• In the current market, the majority of the share was accounted for by the drug UBRELVY, which was around USD 680 million in 2022.
• The emerging pipeline of non-postoperative acute pain contains promising therapies expected to enter the US market during the forecast period (2023-2032). In 2032, among all the therapies, the highest revenue is expected to be generated by VYEPTI (eptinezumab).

Non-postoperative Acute Pain Drugs Uptake

This section focuses on the uptake rate of potential drugs expected to be launched in the market during 2023-2032. The landscape of Non-postoperative acute pain treatment has experienced a profound transformation with the uptake of novel drugs. These innovative therapies are redefining standards of care. Furthermore, the increased uptake of these transformative drugs is a testament to the unwavering dedication of physicians, neurologyic professionals, and the entire healthcare community in their tireless pursuit of acute pain care. This momentous shift in treatment paradigms is a testament to the power of research, collaboration, and human resilience.

Non-postoperative Acute Pain Pipeline Development Activities

The report provides insights into therapeutic candidates in Phase III and Phase II. It also analyzes key players involved in developing targeted therapeutics. Companies like Vertex Pharmaceuticals, Satsuma Pharmaceuticals, Axsome Therapeutics, and Allodynic Therapeutics actively engage in mid and late-stage research and development efforts for Non-postoperative acute pain. The pipeline of Non-postoperative acute pain possesses few potential drugs. However, there is a positive outlook for the therapeutics market, with expectations of growth during the forecast period (2023-2032).

Pipeline Development Activities

The report covers information on collaborations, acquisitions and mergers, licensing, and patent details for Non-postoperative acute pain emerging therapy.

KOL- Views

To keep up with current market trends, we take KOLs and SMEs' opinions working in the domain through primary research to fill the data gaps and validate our secondary research. Industry Experts contacted for insights on the Non-postoperative acute pain evolving treatment landscape, patient reliance on conventional therapies, patient therapy switching acceptability, and drug uptake, along with challenges related to accessibility, including neurologists, physician, and others.

DelveInsight's analysts connected with 30+ KOLs to gather insights; however, interviews were conducted with 15+ KOLs in the United States. Centers such as the Headache and Neurologic Institute, NJ Society of Physical Medicine & Rehabilitation (PM&R), David Geffen School of Medicine, Center for Autonomic and Peripheral Nerve Disorders, etc., were contacted. Their opinion helps understand and validate current and emerging therapy treatment patterns or Non-postoperative acute pain market trends. This will support the clients in potential upcoming novel treatments by identifying the overall scenario of the market and the unmet needs.

Qualitative Analysis

We perform Qualitative and market Intelligence analysis using various approaches, such as SWOT analysis and Analyst views. In the SWOT analysis, strengths, weaknesses, opportunities, and threats in terms of disease diagnosis, patient awareness, patient burden, competitive landscape, cost-effectiveness, and geographical accessibility of therapies are provided. These pointers are based on the analyst's discretion and assessment of the patient burden, cost analysis, and existing and evolving treatment landscape.

Market Access and Reimbursement

LICART is the only once-a-day topical nonsteroidal anti-inflammatory therapy available to treat acute pain due to minor strains, sprains, and contusions. Its patented next-generation patch technology works fast for powerful pain relief that starts within 1-3 h of the first application and can last all day with once-daily dosing. If patients have commercial insurance, can use the LICART Copay Savings Card at any retail pharmacy to get instant savings on their LICART prescription, paying as little as USD 15 for a one-month supply.

In UBRELVY (ubrogepant) savings program, eligible commercially insured patients may pay as little as USD 0 per monthly prescription fill. The patient's out-of-pocket expense will vary; check with the pharmacist for the copay discount. Restrictions, including monthly, quarterly, and/or annual maximums, may apply.

Detailed market access and reimbursement assessment will be provided in the final report.

Scope of the Report:

• The report covers a segment of key events, an executive summary, and a descriptive overview of Non-postoperative acute pain, explaining its causes, signs, symptoms, pathogenesis, and currently used therapies.
• Comprehensive insight into the epidemiology segments and forecasts, disease progression, and treatment guidelines has been provided.
• Additionally, an all-inclusive account of the emerging therapies and the elaborative profiles of late-stage and prominent therapies will impact the current treatment landscape.
• A detailed review of the Non-postoperative acute pain market, historical and forecasted market size, market share by therapies, detailed assumptions, and rationale behind our approach is included in the report, covering the United States drug outreach.
• The report provides an edge while developing business strategies by understanding trends through SWOT analysis and expert insights/KOL views, patient journey, and treatment preferences that help shape and drive the United States Non-postoperative acute pain market.

Non-postoperative Acute Pain Report Insights

• Patient Population
• Therapeutic Approaches
• Non-postoperative acute pain Pipeline Analysis
• Non-postoperative acute pain Market Size and Trends
• Existing and Future Market Opportunity

Non-postoperative Acute Pain Report Key Strengths

• Ten Years Forecast
• The US Coverage
• Non-postoperative acute pain Epidemiology Segmentation
• Key Cross Competition
• Drugs Uptake and Key Market Forecast Assumptions

Non-postoperative Acute Pain Report Assessment

• Current Treatment Practices
• Unmet Needs
• Pipeline Product Profiles
• Market Attractiveness
• Qualitative Analysis (SWOT and Analyst Views)

FAQs

• What was the Non-postoperative acute pain market size, the market size by therapies, market share (%) distribution in 2022, and what would it look like by 2032? What are the contributing factors for this growth?
• What are the pricing variations among the United States for approved therapies?
• What can be the future treatment paradigm for Non-postoperative acute pain?
• What are the disease risks, burdens, and unmet needs of Non-postoperative acute pain? What will be the growth opportunities in the United States concerning the patient population with Non-postoperative acute pain?
• Who is the major competitor of ELYXYB in the market?
• How much market share will Calcitonin gene-related peptide (CGRP) inhibitors capture by 2032?
• What are the current options for the treatment of Non-postoperative acute pain? What are the current guidelines for treating Non-postoperative acute pain in the US?
• What are the recent novel therapies, targets, mechanisms of action, and technologies being developed to overcome the limitations of existing therapies?
• What is the patient share in Non-postoperative acute pain?

Reasons to Buy:

• The report will help develop business strategies by understanding the latest trends and changing treatment dynamics driving the Non-postoperative acute pain market.
• Insights on patient burden/disease incidence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
• Understand the existing market opportunities in varying geographies and the growth potential over the coming years.
• Distribution of historical and current patient share based on real-world prescription data along with reported sales of approved products in the US.
• Identifying strong upcoming players in the market will help devise strategies to help get ahead of competitors.
• Detailed analysis ranking of class-wise potential current and emerging therapies under the analyst view section to provide visibility around leading classes.
• To understand Key Opinion Leaders' perspectives around the accessibility, acceptability, and compliance-related challenges of existing treatment to overcome barriers in the future.
• Detailed insights on the unmet needs of the existing market so that the upcoming players can strengthen their development and launch strategy.

Table of Contents

1. Key Insights

2. Report Introduction

3. Executive Summary of Non-postoperative Acute Pain

4. Non-postoperative Acute Pain Market Overview at a Glance

• 4.1. Market Share by Therapies (%) Distribution of Non-postoperative Acute Pain in 2019 in the US
• 4.2. Market Share by Therapies (%) Distribution of Non-postoperative Acute Pain in 2032 in the US

5. Key Events

6. Epidemiology and Market Methodology

7. Disease Background and Overview

• 7.1. Introduction
• 7.2. Acute Pain vs. Chronic Pain
• 7.3. Types of Acute Pain
• 7.4. Signs and Symptoms
• 7.5. Causes of Non-postoperative Acute Pain
• 7.6. Diagnosis
  • 7.6.1. Medical History, Physical Examination, and Specific Evaluation of Pain
  • 7.6.2. Measuring Pain
  • 7.6.3. Various Grading Scales for the Diagnosis of Acute Pain
    • 7.6.3.1. Visual Analogue Scale
    • 7.6.3.2. Verbal Rating Scale
    • 7.6.3.3. Graded Chronic Pain Scale (GCPS)
    • 7.6.3.4. Numeric Rating Scale (NRS)
  • 7.6.4. Verbal Methods of Pain Assessment
  • 7.6.5. Multidimensional Methods of Pain Assessment
  • 7.6.6. Nonverbal Methods of Pain Assessment
  • 7.6.7. Diagnostic Algorithm

8. Treatment

• 8.1. Pharmacological Management
  • 8.1.1. Multimodal Analgesia
  • 8.1.2. Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
  • 8.1.3. Topical Agents
  • 8.1.4. Anticonvulsants
  • 8.1.5. Opioids
  • 8.1.6. Non-opioid Analgesics
• 8.2. Nonpharmacological Treatments for Acute Pain
  • 8.2.1. Herbal Medicine
  • 8.2.2. Homeopathy
  • 8.2.3. Physical Methods
  • 8.2.4. Hypnosis
  • 8.2.5. Immobilization
  • 8.2.6. Physical Therapy
  • 8.2.7. Massage
• 8.3. Treatment Guidelines
  • 8.3.1. CDC Clinical Practice Guideline for Prescribing Opioids for Pain (2022)
  • 8.3.2. American Academy of Family Physicians: Pharmacologic Therapy for Acute Pain (2021)
  • 8.3.3. Nonpharmacologic and Pharmacologic Management of Acute Pain from Non-Low Back, Musculoskeletal Injuries in Adults: A Clinical Guideline From the American College of Physicians and American Academy of Family Physicians (2020)

9. Epidemiology and Patient Population

• 9.1. Key Findings
• 9.2. Assumptions and Rationale: Non-postoperative Acute Pain
• 9.3. Epidemiology Scenario in the United States
  • 9.3.1. Total Incident Cases of Non-postoperative Acute Pain in the United States
  • 9.3.2. Type-specific Cases of Non-postoperative Acute Pain in the United States
  • 9.3.3. Severity-specific Cases of Non-postoperative Acute Pain in the United States
  • 9.3.4. Total Treated Cases of Non-postoperative Acute Pain in the United States

10. Patient Journey

11. Marketed Therapies

• 11.1. Marketed Key Cross Competition
• 11.2. LICART (diclofenac epolamine): IBSA Institut Biochimique
  • 11.2.1. Product Description
  • 11.2.2. Regulatory Milestones
  • 11.2.3. Clinical Development
    • 11.2.3.1. Clinical Trials Information
  • 11.2.4. Safety and Efficacy
• 11.3. UBRELVY (ubrogepant): Allergan/AbbVie
  • 11.3.1. Product Description
  • 11.3.2. Regulatory Milestones
  • 11.3.3. Other Developmental Activities
  • 11.3.4. Clinical Development
    • 11.3.4.1. Clinical Trials Information
  • 11.3.5. Safety and Efficacy
• 11.4. REYVOW (lasmiditan): Eli Lilly
  • 11.4.1. Product Description
  • 11.4.2. Regulatory Milestones
  • 11.4.3. Clinical Development
    • 11.4.3.1. Clinical Trials Information
  • 11.4.4. Safety and Efficacy
• 11.5. ZAVZPRET (zavegepant): Pfizer
  • 11.5.1. Product Description
  • 11.5.2. Regulatory Milestones
  • 11.5.3. Other Developmental Activities
  • 11.5.4. Clinical Development
    • 11.5.4.1. Clinical Trials Information
  • 11.5.5. Safety and Efficacy
• 11.6. NURTEC ODT (rimegepant): Pfizer/ Biohaven
  • 11.6.1. Product Description
  • 11.6.2. Regulatory Milestones
  • 11.6.3. Other Developmental Activities
  • 11.6.4. Clinical Development
    • 11.6.4.1. Clinical Trials Information
  • 11.6.5. Safety and Efficacy
• 11.7. EMGALITY (galcanezumab-gnlm): Eli Lilly
  • 11.7.1. Product Description
  • 11.7.2. Regulatory Milestones
  • 11.7.3. Other Developmental Activities
  • 11.7.4. Safety and Efficacy
• 11.8. ELYXYB (celecoxib): Scilex Holding
  • 11.8.1. Product Description
  • 11.8.2. Regulatory Milestones
  • 11.8.3. Other Developmental Activities
  • 11.8.4. Safety and Efficacy
• 11.9. TRUDHESA (dihydroergotamine mesylate): Impel Pharmaceuticals
  • 11.9.1. Product Description
  • 11.9.2. Regulatory Milestones
  • 11.9.3. Other Developmental Activities
  • 11.9.4. Safety and Efficacy

12. Emerging Therapies

• 12.1. Emerging Key Cross Competition
• 12.2. VX-548: Vertex Pharmaceuticals
  • 12.2.1. Product Description
  • 12.2.2. Clinical Development
    • 12.2.2.1. Clinical Trials Activities
• 12.3. Eptinezumab: H. Lundbeck A/S
  • 12.3.1. Product Description
  • 12.3.2. Other Developmental Activity
  • 12.3.3. Clinical Development
    • 12.3.3.1. Clinical Trials Activities
• 12.4. STS101 (DHE Nasal Powder): Satsuma Pharmaceuticals
  • 12.4.1. Product Description
  • 12.4.2. Other Developmental Activities
  • 12.4.3. Clinical Development
    • 12.4.3.1. Clinical Trials Activities
  • 12.4.4. Safety and Efficacy
• 12.5. AXS-07: Axsome Therapeutics
  • 12.5.1. Product Description
  • 12.5.2. Other Developmental Activities
  • 12.5.3. Clinical Development
    • 12.5.3.1. Clinical Trials Activities
  • 12.5.4. Safety and Efficacy
• 12.6. Naltrexone-Acetaminophen: Allodynic Therapeutics
  • 12.6.1. Product Description
  • 12.6.2. Other Developmental Activity
  • 12.6.3. Clinical Development
    • 12.6.3.1. Clinical Trials Activities
  • 12.6.4. Safety and Efficacy

13. Non-postoperative Acute Pain: The US Market Analysis

• 13.1. Key Findings
• 13.2. Market Outlook
• 13.3. Conjoint Analysis
• 13.4. Key Market Forecast Assumptions
• 13.5. United States Market Size
  • 13.5.1. Total Market Size of Non-postoperative Acute Pain in the United States
  • 13.5.2. Market Size of Non-postoperative Acute Pain by Therapies in the United States

14. Unmet Needs

15. SWOT Analysis

16. KOL Views

17. Market Access and Reimbursement

• 17.1. United States
  • 17.1.1. Centre for Medicare and Medicaid Services (CMS)
• 17.2. Market Access and Reimbursement of Non-postoperative Acute Pain

18. Appendix

• 18.1. Acronyms and Abbreviations
• 18.2. Bibliography
• 18.3. Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight